epictrial.comEPIC Study: Official Site

Epic study results 1 st EPIC STUDY PUBLICATION 2 nd EPIC STUDY PUBLICATION Why is the epic study important? Hear from the investigators What the epic study means for dogs and pet owners Diagnosing and managing preclinical MMVD About the epic study About the epic study Epic study design Epic study investigators Epic study locations Classification of canine heart disease Classification of canine heart disease Diagnosing preclinical MMVD Treatment options for heart disease FAQs Helpful links Contact The results are EPIC 1,2 Groundbreaking results of the EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history, are now published. 15- month delay in time to composite primary endpoint compared with dogs receiving placebo* 60% more time in asymptomatic stage B2 of heart disease* 10% more life without CHF signs that impact quality of life or cardiac-related death † PROVEN BENEFITS OF EARLY TREATMENT OF MYXOMATOUS MITRAL VALVE DISEASE (MMVD)—BEFORE CONGESTIVE HEART FAILURE (CHF) 1 The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical MMVD—before the onset of CHF, cardiac-related death, or euthanasia (composite primary endpoint). VIEW FINDINGS WHAT DOES THE EPIC STUDY MEAN FOR VETERINARIANS? Discover how veterinarians can apply the findings of the EPIC Study to their clinical practice. LEARN WHY THE EPIC STUDY IS SO IMPORTANT HEAR FROM THE INVESTIGATORS The EPIC Study represents a significant advancement in canine cardiology. Watch the lead investigators discuss the implications of this groundbreaking study. WATCH NOW WHAT DOES THE EPIC STUDY MEAN FOR DOGS AND THEIR OWNERS? For pet owners, the EPIC Study results demonstrate how early treatment of MMVD can help dogs live longer, free from the symptoms of CHF. LEARN MORE DIAGNOSING AND MANAGING PRECLINICAL MMVD EPIC Study results can empower veterinarians to identify MMVD early and achieve better outcomes for their patients. LEARN MORE DETAILS ABOUT THE EPIC STUDY First published in 2016, the EPIC Study is the largest prospective, randomised clinical study in veterinary cardiology history 1 centres dogs double-blinded placebo-controlled countries years GET THE STUDY RESULTS RESULTS ARE IN! Use of pimobendan significantly reduced heart size in dogs with Stage B2 myxomatous mitral valve disease (MMVD) 1,2 SIGNIFICANT CHANGE WITHIN 1 MONTH REDUCTION IN HEART SIZE MORE TIME VIEW FINDINGS References: 1. Boswood A, Häggström J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study—a randomized clinical trial. J Vet Intern Med. 2016;30:1765–1779. 2. Boswood A, Gordon SG, Häggström J, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical myxomatous mitral valve disease receiving pimobendan or placebo: the EPIC Study. J Vet Intern Med. 2018;32(1):72–85. * The composite primary endpoint was defined as the onset of left-sided CHF, cardiac-related death, or euthanasia; dogs in the pimobendan group were significantly less likely to reach this endpoint. Median time to composite primary endpoint was 1228 days in the pimobendan group and 766 days in the placebo group ( P =0.0038). † Ten percent more life without CHF was calculated based on an estimated lifespan for all small- to medium-sized dogs being 12.5 years. Fifteen months is equal to 1.25 years, which is 10% of 12.5 years. All trademarks mentioned are the property of Boehringer Ingelheim Vetmedica GmbH. © 2019 Boehringer Ingelheim Vetmedica GmbH. Terms of Use Data Policy Site Map This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information welcome to EPICtrial.com Disclaimer Are you a resident of the United States of America? Yes No Submit INFORMATION DISCUSSED ON EPICTRIAL.COM RELATES TO AN INDICATION THAT IS NOT REGISTERED IN THE USA. You will now be redirected to a USA-specific website. CONTINUE...